Inventor
BURKE JAMES A
US48 patents
⚠️ This page may combine multiple inventors who share the name “BURKE JAMES A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALLERGAN INC
34 patentsUS7931909B2Apr 26, 2011
Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
ALLERGAN INC64 citations98
US6841684B2Jan 11, 2005
Imidiazoles having reduced side effects
ALLERGAN INC72 citations97
US5773440AJun 30, 1998
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ALLERGAN INC32 citations96
US5756503AMay 26, 1998
Methods for using (2-imidazolin-2-ylamino) Quinoxaline derivatives
ALLERGAN INC55 citations96
US5703077ADec 30, 1997
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ALLERGAN INC49 citations96
US5561132AOct 1, 1996
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ALLERGAN INC47 citations96
US5552403ASep 3, 1996
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ALLERGAN INC28 citations96
US5281591AJan 25, 1994
Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
ALLERGAN INC62 citations96
US5215991AJun 1, 1993
Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
ALLERGAN INC73 citations96
US6323204B1Nov 27, 2001
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ALLERGAN INC46 citations93
US5714486AFeb 3, 1998
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ALLERGAN INC22 citations93
US5587376ADec 24, 1996
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ALLERGAN INC24 citations93
US5418234AMay 23, 1995
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ALLERGAN INC22 citations93
US5373010ADec 13, 1994
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ALLERGAN INC22 citations93
US5326763AJul 5, 1994
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ALLERGAN INC28 citations93
US5231096AJul 27, 1993
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ALLERGAN INC24 citations93
US5180721AJan 19, 1993
Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
ALLERGAN INC38 citations93
US5021410AJun 4, 1991
Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
ALLERGAN INC30 citations93
US9061065B2Jun 23, 2015
Intracameral sustained release therapeutic agent implants
ALLERGAN INC15 citations92
US10278919B2May 7, 2019
Intracameral sustained release therapeutic agent implants
ALLERGAN INC10 citations84
US9504696B2Nov 29, 2016
Intracameral sustained release therapeutic agent implants
ALLERGAN INC8 citations84
US10653621B2May 19, 2020
Biodegradable drug delivery systems for the sustained release of proteins
ALLERGAN INC9 citations83
US6706747B2Mar 16, 2004
Conformationally rigid bicyclic and adamantane derivatives useful as α2-adrenergic blocking agents
ALLERGAN INC4 citations74
US5708015AJan 13, 1998
Method for using pharmaceutical compositions containing 2-(2-alkyphenyl-amino)-thiazolines as adrenergic agents
ALLERGAN INC10 citations74
US10363214B2Jul 30, 2019
Method for treating atrophic age related macular degeneration
ALLERGAN INC3 citations73
US10201641B2Feb 12, 2019
Sustained release intraocular implants and methods for treating ocular vasculopathies
ALLERGAN INC1 citations71
US11096958B2Aug 24, 2021
Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity
ALLERGAN INC1 citations67
US6569884B2May 27, 2003
Conformationally rigid bicyclic and adamantane derivatives useful as α2-adrenergic blocking agents
ALLERGAN INC2 citations63
US5731337AMar 24, 1998
Conformationally rigid bicycle and adamantane derivatives useful as α2
ALLERGAN INC4 citations63
US8353862B2Jan 15, 2013
Drug delivery systems and methods
ALLERGAN INC2 citations60
US12527816B2Jan 20, 2026
Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity
ALLERGAN INC0 citations56
US11738043B2Aug 29, 2023
Sodium chlorite compositions with enhanced antimicrobial efficacy and reduced toxicity
ALLERGAN INC0 citations56
US9572859B2Feb 21, 2017
Compositions and methods for localized therapy of the eye
ALLERGAN INC1 citations52
US9144543B2Sep 29, 2015
Sustained release intraocular implants and methods for preventing retinal dysfunction
ALLERGAN INC0 citations48
ALLERGAN SALES INC
4 patentsUS6329369B1Dec 11, 2001
Methods of treating pain and other conditions
ALLERGAN SALES INC83 citations97
US6087361AJul 11, 2000
Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects
ALLERGAN SALES INC32 citations92
US6319935B1Nov 20, 2001
Conformationally rigid bicyclic and adamantane derivatives useful as α2-adrenergic blocking agents
ALLERGAN SALES INC4 citations74
US6150389ANov 21, 2000
Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents
ALLERGAN SALES INC8 citations74
HUANG GLENN T
3 patentsUS9161938B2Oct 20, 2015
Sustained release intraocular implants and methods for treating ocular vasculopathies
HUANG GLENN T6 citations82
US8506986B2Aug 13, 2013
Sustained release intraocular implants and methods for treating ocular vasculopathies
HUANG GLENN T4 citations72
US8580292B2Nov 12, 2013
Sustained release intraocular implants and methods for treating ocular vasculopathies
HUANG GLENN T0 citations51